Skip to main content
. Author manuscript; available in PMC: 2012 Aug 16.
Published in final edited form as: Cancer Cell. 2011 Aug 16;20(2):187–199. doi: 10.1016/j.ccr.2011.06.016

Figure 6. Coordinated expression of PcG proteins and PRC regulatory miRNAs in prostate cancer progression.

Figure 6

(A) Expression of indicated miRs as assessed by q-PCR in benign prostate, clinically localized prostate cancer and metastatic prostate cancer tissues. Data for EZH2, miR-217 and miR-101 was reported previously (Varambally et al., 2008) and displayed here for comparison (Student's t test). (B) Immunoblot analysis of EZH2, BMI-1, RING2, RING1 and ubiquityl-H2A in benign prostate, clinically localized prostate cancer and metastatic prostate cancer. (C) Bisulfite sequencing analysis of the miR-203 genomic region revealed cancer-specific DNA methylation in a region proximal to miR-203 in prostate cancer tissues. All bar graphs are shown with ±SEM. See also Figure S6.